Table 3.

Multiple regression analysis of outcomes after nonmyeloablative umbilical cord blood transplantation

Outcome	Odds ratio, relative risk (95% CI)	P
Graft failure
HLA match 4/6*	5.0 (0.6-41.5)	.14
Double UCB donor†	2.4 (0.3-20.8)	.42
TNC dose‡
2.9 to 3.6 × 107/kg	1.5 (0.2-9.8)	.62
3.7 to 4.3 × 107/kg	3.2 (0.6-18.2)	.18
No less than 4.4 × 107/kg	2.6 (0.4-16.3)	.31
Grades II-IV acute GVHD
Double UCB donor†	2.3 (1.0-5.1)	.04
No ATG in the preparative regimen§	2.2 (1.2-4.0)	<.01
Transplantation-related mortality‖:
Pretransplantation high-risk clinical features¶	3.9 (1.6-9.1)	<.01
Event-free survival
Double UCB donor†	0.6 (0.3-1.0)	.07
Pretransplantation high-risk clinical features¶	2.2 (1.3-3.8)	<.01
Overall survival#
Pretransplantation high-risk clinical features¶	3.0 (1.7-5.2)	<.01
Grades III and IV acute GVHD**	1.9 (1.0-3.5)	.04

Odds ratios are in rows 1 through 7, relative risk in rows 8 to end.

^*HLA match 5-6/6 (baseline odds ratio of 1.0). For recipients of 2 UCB units we considered the HLA-matching of the worst matched unit.

^†Single UCB donor unit (baseline odds ratio or relative risk of 1.0).

^‡TNC dose less than 2.9 × 10⁷/kg (baseline odds ratio of 1.0).

^§Presence of ATG in the preparative regimen (baseline relative risk of 1.0).

^‖Causes of transplant-related death at 6 months included GVHD,³ graft failure,¹ EBV-induced lymphoma,¹ multiple organ failure/infection,¹² and hemorrhage.³

^¶Absence of high-risk clinical features (baseline relative risk of 1.0).

^#Overall causes of death included disease relapse or progression,²⁷ infection and organ failure,¹² GVHD,⁶ hemorrhage,³ and EBV-induced posttransplant lymphoproliferative disease,² multiple organ failure,² and graft failure.¹

^**Absence of grades III and IV acute GVHD (baseline relative risk of 1.0).